The Central Drugs Standard Control Organization (CDSCO) is advancing a smarter, risk-based regulatory framework aimed at simplifying compliance for Indian pharmaceutical manufacturers while strengthening drug safety oversight. The initiative was highlighted at iPHEX 2026, India’s flagship pharma export showcase, where regulators and industry leaders discussed the future of drug regulation in the country.
Why Risk-Based Regulation Matters
Under a risk-based model, CDSCO allocates its inspection and approval resources based on the risk profile of each manufacturer and product. Higher-risk facilities — such as those producing sterile injectables or novel drug formulations — would face more frequent and rigorous oversight, while established manufacturers with consistent compliance records could benefit from streamlined processes.
This approach mirrors regulatory models already adopted by the U.S. FDA and the European Medicines Agency (EMA), both of which use risk-stratified inspection scheduling to optimize resource allocation without compromising patient safety.
What iPHEX 2026 Revealed
The iPHEX 2026 exhibition, held in New Delhi, brought together domestic and international pharma stakeholders to discuss export opportunities, regulatory alignment, and quality standards. According to coverage by Express Pharma (September 9, 2026), CDSCO officials used the platform to signal a shift toward smarter, more efficient regulation — one that reduces bureaucratic friction for compliant manufacturers while maintaining strict oversight where it matters most.
The event also saw significant business momentum: multiple sources reported that iPHEX 2026 generated between $4.5 billion and $5 billion in potential business discussions, underscoring the global demand for Indian generic medicines and active pharmaceutical ingredients (APIs).
Key Benefits for the Indian Pharma Industry
- Reduced compliance burden for manufacturers with strong quality track records, freeing resources for innovation and expansion.
- Focused inspections on high-risk facilities, improving the likelihood of catching compliance issues before they become public health concerns.
- Faster approval pathways for low-risk product categories, helping Indian exporters respond more quickly to international market demand.
- Alignment with global standards — risk-based regulation is increasingly the norm in major pharmaceutical markets, making Indian manufacturers more competitive internationally.
Implications for Buyers of Indian Generic Medicines
For international buyers and regulatory authorities sourcing generic medicines from India, a risk-based CDSCO framework could mean greater confidence in the quality of exported products. Manufacturers that consistently meet WHO-GMP standards and maintain transparent compliance records are likely to face fewer regulatory hurdles — and their products may reach global markets faster.
However, buyers should continue to conduct their own due diligence. A risk-based approach from the regulator does not replace the need for importers to verify manufacturer credentials, request certificates of analysis, and audit supply chains independently. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
What Comes Next
While the risk-based regulation concept has been discussed publicly, the specific operational details — including how manufacturers will be classified by risk tier, what data CDSCO will use for stratification, and the timeline for implementation — have not yet been formally announced. The DCGI’s office has indicated that further guidelines are under development.
Industry observers expect the framework to be rolled out in phases, beginning with export-oriented manufacturers who already operate under international quality standards, before extending to the broader domestic market.
Source: Express Pharma, “CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026,” September 9, 2026. Additional context from iPHEX 2026 business deal reports (Indian Pharma Post, BW Healthcare World, September 2026).
For more information, contact IMSDA at contact@indiamedicine.org.